Real-world evidence/ RWE solution Market Covid-19 Impact, Therapeutic Area, End-User, Geography and Top Companies IBM Corporation, ICON plc, IQVIA, Optum, Oracle Corporation

The Real-world evidence/ RWE solution Market report provides a detailed analysis, of the market for the period of start year-end year. The report provides information about the CAGR, sales, and revenue studying the historical data and making an estimation of the revenue growth till the forecast period. The key objective of this Real-world evidence/ RWE solution Market report is to deliver an all-inclusive summary including the market share, market size, opportunities, market influencers, challenges, driving factors, and growth rate, by the deep-dive study of the leading market players of healthcare industry from different geographical locations, their product/service types and application industries.

Get a FREE Sample Copy of this Report with Graphs and Charts at: https://www.businessworldeco.com/request-sample/38/

The global Real-world evidence/ RWE solution market is estimated to gain the highest CAGR of 14.4% & is projected to reach USD 1.2 billion in 2021 to USD 2.3 billion by 2026. Real-world evidence is utilized to examine the post-market security and adverse events of drugs. RWE and RWD are mainly used in the healthcare industry to support coverage decisions and develop guidelines during clinical practice.

Key players in the RWE solutions Market

IBM Corporation (U.S.),
ICON plc (Ireland),
IQVIA (U.S.),
Optum (a subsidiary of United Health Group, Inc.) (U.S.),
Oracle Corporation (U.S.),
PAREXEL International Corporation (U.S.),
PerkinElmer, Inc. (U.S.),
PPD Inc., (U.S.),
SAS Institute Inc. (U.S.),
and Syneos Health, Inc. (U.S.),
Anthem, Inc. (U.S.),
Clinigen Group plc (U.K.),
Cognizant Technology Solutions Corporation (U.S.)
and others.

Real-world evidence/ RWE solution Market report offers the list of chief competitors and provides strategic insights and analysis of key factors influencing the industry. This market analysis makes businesses acquainted with various segments that are relied upon to observe the rapid business development amid the estimated forecast frame. This market research report has wide-ranging and comprehensive market insights which are based on business intelligence. This Real-world evidence/ RWE solution Market report best suits the requirements of clients. A panel of skilled analysts, well-versed statisticians, knowledgeable research experts, enthusiastic forecasters, and smart economists work carefully to generate such excellent market research report for businesses.

Key Benefits of Purchasing Report:

The report provides comprehensive information about the product portfolios, recent developments, growing regions, and real-world evidence solutions market investment. In addition, the report analyzes real-world evidence markets by type of component, end-user, therapeutic area, and region.

The report also provides a competitive assessment of market share, growth strategies, capabilities, and product offers of the key market player in the RWE solutions market. The research report will help new entrants/stakeholders understand and analyze upcoming challenges and opportunities.

The rapid increase in chronic diseases is the primary factor driving the market growth. In addition, the shift from volume-to-value-based care, delays in drug development, support from regulatory bodies for the usage of RWE solutions are some key factors responsible for boosting the market in the estimated period.

The Covid -19 pandemic has impacted the healthcare sector due to the tremendous burden on healthcare authorities across the globe. Rise in Covid cases, the vulnerability of the medical staff, shortage of treatment, Overall healthcare sector is struggling to deal with the pandemic situation. RWE solution can understand and prepare strategies to deal with upcoming challenges caused due to pandemics. However, the lack of universally accepted methodological standards for data collection is the drawback restraining RWE solutions market growth.

Get 20% Discount on this Research Report at: https://www.businessworldeco.com/discount-request/38/

The rise in Development costs is projected to propel market growth.

Due to the hike in rare diseases, the healthcare section faces obstacles posed by the expensive and lengthy duration of delivering medicines to patients. This delay is time-consuming to develop a new pharmaceutical entity, is highly costly, and of high risk with little chance of successful outcome.

The increasing price and time-consuming clinical trials demoralize pharmaceutical organizations from drug development, limiting patients’ access to novel treatments. Due to the high cost of clinical trials and drug development, most organizations are looking for viable ways to lower the cost and avoid drug development barriers to accelerate the drug development process. The acquisition of RWE solutions helps access and lower burdens on the healthcare sector and better understand medicines usage in the real world.

The services and Oncology segments witnessed the largest market share in 2020

In 2020, the services segment witnessed a larger share of 58.8%, whereas the oncology segment witnessed the largest share of 24.% of the global RWE solutions market. As a result, the services segment is projected to grow at the highest CAGR of 16.0% during the forecast period. In addition, the increasing need to convert data into actionable evidence, the rising need to reduce drug developments delays, and the availability of healthcare data are the key factors driving the market growth of the services segment.

Moreover, The REW solutions market is classified into neurology, oncology, immunology, cardiovascular diseases, and other therapeutic areas. The oncology segment is estimated to reach USD 285.5 million in 2021 to USD 560.5 million by 2026. The more significant number of clinical trials conducted for oncology and the rising prevalence of cancer worldwide can be attributed to the oncology segment’s large share.

The pharmaceutical and medical device companies segment accounted for the largest market share in 2020

The pharmaceutical and medical device organizations segment witnessed the largest share of 46.3% of the RWE solutions market in 2020. This segment is also projected to grow at the highest CAGR of 16.8% during the forecast period. Based on the end-user, the RWE solutions market is classified into medical device companies, healthcare prayers, healthcare providers, pharmaceuticals, and other end users like academic institutions, health technology assessment agencies, and patients advocacy groups.

North America is the largest region to witness the highest CAGR.

In 2020, North America experienced the largest share of 60.8% of the global RWE solutions market. An increasing number of RWE service providers, favorable regulatory environment, increasing number of payers using RWD, and the increasing number of pharmaceutical companies adopting RWE for the drug development process are the factors that boost the growth of the RWE market in North America.

The global RWE solutions market is categorized into five major regions: Asia Pacific, North America, Latine America, and the Middle East & Africa. However, the Asia Pacific region is projected to grow at the highest CAGR during the forecast period.

Research Report includes :

The report provides in-depth insights into the RWE solutions market and analyzes market growth during the estimated period. In addition, it includes the growth potential of different market segments based on end-user, component, services, therapeutic area, and region.

The report also provides information about market drivers and restraints to help stakeholders and new entrants make robust business strategies. Additionally, it provides information about key players operating in the market and their recent developments, company profiles, and product offering.

Table Of Contents

1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.2.1 Inclusions And Exclusions
1.2.2 Markets Covered
1.2.3 Years Considered For The Study
1.3 Currency
Table 1 Exchange Rates Utilized For Conversion To Usd
1.4 Limitations
1.5 Stakeholders
1.6 Summary Of Changes

2 Research Methodology
2.1 Research Data
Figure 1 Research Design
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
Figure 2 Primary Sources
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Insights From Primary Experts
Figure 3 Breakdown Of Primary Interviews: Supply-Side And Demand-Side Participants
Figure 4 Breakdown Of Primary Interviews (Supply Side): By Company Type, Designation, And Region
2.2 Market Size Estimation: RWE Solutions Market
Figure 5 Supply-Side Market Size Estimation: Revenue Share Analysis
Figure 6 Cagr Projections: Overall Real-World Evidence Solutions Market
2.2.1 Top-Down Approach
2.3 Market Breakdown And Data Triangulation
Figure 7 Data Triangulation Methodology
2.4 Market Ranking Analysis
2.5 Assumptions For The Study
2.6 Risk Assessment
Table 2 Risk Assessment: Real-World Evidence Solutions Market
2.7 Limitations
2.7.1 Methodology-Related Limitations
2.7.2 Scope-Related Limitations

3 Executive Summary
Figure 8 Real-World Evidence Solutions Market, By Component, 2021 Vs. 2026 (Usd Million)
Figure 9 Real-World Evidence Solutions Market, By Therapeutic Area, 2021 Vs. 2026 (Usd Million)
Figure 10 Real-World Evidence Solutions Market, By End User, 2021 Vs. 2026 (Usd Million)
Figure 11 Real-World Evidence Solutions Market: Geographic Snapshot

4 Premium Insights
4.1 Real-World Evidence Solutions Market Overview
Figure 12 Support From Regulatory Bodies For The Use Of RWE Solutions Is A Major Factor Driving The Market Growth
4.2 Asia Pacific: Real-World Evidence Solutions Market, By End User And Country (2020)
Figure 13 Japan Accounted For The Largest Share Of Theasia Pacific Market In 2020
4.3 Real-World Evidence Solutions Market: Geographic Growth Opportunities
Figure 14 China To Register The Highest Growth Rate During The Forecast Period
4.4 Regional Mix: Real-World Evidence Solutions Market (2021?2026)
Figure 15 North America Will Continue To Dominate The Real-World Evidence Solutions Market During The Forecast Period
4.5 Real-World Evidence Solutions Market: Developed Vs. Developing Markets
Figure 16 Developing Markets To Register Higher Growth Rates During The Forecast Period

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
Table 3 Drivers, Restraints, Opportunities, And Challenges: Impact Analysis
5.2.1 Drivers
5.2.1.1 Rising Geriatric Population And The Subsequent Increase In The Prevalence Of Chronic Diseases
Figure 17 Growth In The Geriatric Population, By Region (2015–2050)
5.2.1.2 Shift From Volume- To Value-Based Care
5.2.1.3 Potential Of RWE In Reducing Drug Development Costs And Expediting The Drug Development Process
5.2.1.4 Growth In R&D Spending
Figure 18 Increasing R&D Spending Of Phrma Member Companies, 2010–2018
Figure 19 Active Pharmaceutical Pipeline, 2009–2019
5.2.1.5 Support From Regulatory Bodies For The Use Of RWE Solutions
5.2.2 Restraints
5.2.2.1 Reluctance To Rely On Real-World Studies
5.2.3 Opportunities
5.2.3.1 Growth Opportunities In Emerging Markets
5.2.3.2 Rising Focus On End-To-End RWE Services
5.2.4 Challenges
5.2.4.1 Lack Of Universally Accepted Methodological Standards And Data Processing Infrastructure
5.2.4.2 Shortage Of Skilled Professionals

6 Industry Insights
6.1 Industry Trends
6.1.1 Emerging Role Of Wearable Devices
Figure 20 Utilization Of Wearables In Clinical Trials, By Therapeutic Area (2019)
6.1.2 Social Media-Sourced Rwe
6.1.3 Growing Use Of Rwd And RWE Across The Pharmaceutical Industry
Figure 21 Recommended Investment Model For Rwd And Rwe
6.1.4 Internal Vs. Outsourced RWE Analytics Approach
Figure 22 Internal Vs. Outsourced RWE Analytics Approach
6.1.5 Incorporation Of Artificial Intelligence In Rwd Management
6.2 Real-World Data Sources
Table 4 Indicative List Of National Databases In Developed Countries
6.3 Ecosystem Analysis
Figure 23 Ecosystem Coverage: Parent Market (Healthcare It Solutions)
Figure 24 Ecosystem Coverage: Real-World Evidence Solutions Market
6.4 Covid-19 Impact On The Real-World Evidence Solutions Market
6.5 Regulatory Recommendations For Real-World Evidence Solutions
6.5.1 North America
6.5.2 Europe
6.5.3 Asia Pacific
6.6 Hcit Expenditure/Pricing Analysis
6.6.1 North America
Table 5 North America: Healthcare Expenditure, By Country
6.6.2 Europe
6.6.3 Asia Pacific
Table 6 Japan: Healthcare It Initiatives And Funding
Table 7 China: Healthcare It Initiatives And Funding

7 RWE Solutions Market, By Component

8 RWE Solutions Market, By Therapeutic Area

9 RWE Solutions Market, By End User

10 RWE Solutions Market, By Region

Purchase this report at: https://www.businessworldeco.com/buy-now/38/

CONTACT INFO:

Magarpatta City, Hadapsar, Pune, India - 411013
+ 1 888 391 5441
sales@businessworldeco.com

www.businessworldeco.com

This release was published on openPR.